0.47
-0.0199(-4.06%)
Currency In USD
| Previous Close | 0.49 |
| Open | 0.5 |
| Day High | 0.5 |
| Day Low | 0.47 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 5.03M |
| Average Volume | 5.88M |
| Market Cap | 28.44M |
| PE | -0.49 |
| EPS | -0.96 |
| Moving Average 50 Days | 0.57 |
| Moving Average 200 Days | 0.55 |
| Change | -0.02 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.03 as of January 14, 2026 at a share price of $0.47. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $13.22 as of January 14, 2026 at a share price of $0.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
GlobeNewswire Inc.
Jan 08, 2026 12:30 PM GMT
On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthca
Plus Therapeutics Expands CNSide Assay Platform to State of California
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Compan
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
GlobeNewswire Inc.
Dec 09, 2025 12:30 PM GMT
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syste